Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.52 |
| ▸ | PROKR1 | Q8TCW9 | 6/20 | 0.52 |
| ▸ | HRH1 | P35367 | 14/20 | 0.48 |
| ▸ | CCR3 | P51677 | 14/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020187 | 0.89 | FPR2 (0.49) | FPR2PROKR1HRH1CCR3 | |
| SCHEMBL8777604 | 0.84 | FPR2 (0.48) | FPR2PROKR1 | |
| SCHEMBL4753890 | 0.82 | FPR2 (0.51) | FPR2PROKR1HRH1CCR3KCNH2 | |
| SCHEMBL4752287 | 0.71 | FPR2 (0.48) | FPR2PROKR1HRH1CCR3KCNH2 | |
| SCHEMBL5020541 | 0.70 | HRH1 (0.47) | FPR2PROKR1HRH1CCR3KCNH2 | |
| SCHEMBL8111588 | 0.70 | HRH1 (0.46) | FPR2PROKR1HRH1CCR3KCNH2 | |
| SCHEMBL5020141 | 0.69 | GPR119 (0.41) | — | |
| SCHEMBL5406534 | 0.69 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL15550382 | 0.69 | FPR2 (1.00) | FPR2PROKR1 | |
| SCHEMBL5020140 | 0.67 | GRIN2D (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623892-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012064943-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FPR2 2862/4885PROKR1 3666/4885HRH1 3358/4885 |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FPR2 2862/4885PROKR1 3666/4885HRH1 3358/4885 |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FPR2 2862/4885PROKR1 3666/4885HRH1 3358/4885 |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FPR2 2862/4885PROKR1 3666/4885HRH1 3358/4885 |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FPR2 2862/4885PROKR1 3666/4885HRH1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.